Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Medifast financials data including stock price, CreditSafe score, income statement, balance sheet, cash flow, and acquistions and subsidiaries.
Stock Price
$18.5
2024-10-29
Market Capitalization
$202.5 M
2024-10-29
Revenue
$1.1 B
FY, 2023
CreditSafe Score
?
Score changed on Jan 23, 2025
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|
| Revenue | 1.5B | 1.6B | 1.1B |
| Cost of goods sold | 398.5M | 458.2M | 296.2M |
| Gross profit | 1.1B | 1.1B | 775.9M |
| Gross profit margin, % | 73.9% | 71.3% | 72.4% |
| General and administrative expense | 911.4M | 955.6M | 649.4M |
| Operating expense total | 911.4M | 955.6M | 649.4M |
| EBIT | 216.2M | 184.8M | 126.4M |
| EBIT margin, % | 14.2% | 11.6% | 11.8% |
| Interest income | 2.5M | ||
| Interest expense | 231.0K | 701.0K | |
| Pre tax profit | 216.1M | 184.1M | 128.8M |
| Income tax expense | 52.1M | 40.5M | 29.4M |
| Net Income | 164.0M | 143.6M | 99.4M |
| EPS | 13.9 | 12.7 | 9.1 |
Acquisitions & Subsidiaries
| Company name | Date | Deal size |
|---|---|---|
| Lorem | Dec 23, 2021 | $40.0M |
| Ipsum | Jan 18, 2022 | $30.0M |
| Lorem Ipsum | Feb 18, 2022 | $25.0M |
| Dolor | Oct 21, 2021 | $60.0M |
Premium Content only available in Craft’s Intelligence Portal View acquisitions and subsidiaries by company, date, and deal size. Understanding this data enables better supplier & customer negotiations and helps identify potential opportunities or market risks for your firm. Learn more |